Bevacizumab, a humanised monoclonal antibody against VEGF, blocks angiogenesis and thereby reduces tumour growth in a variety of GBM mouse models as a monotherapy and when combined with radiotherapy (72–75). Here, VEGFA is linked to glioblastoma.